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BACKGROUND: Nontuberculous mycobacterial (NTM) 
infections have radically increased worldwide due to the increase 
in HIV infections. The disease activity increases with progressive 
immunodeficiency.  
METHODS: A total of 216 HIV seropositive patients suspected 
of having mycobacterial infection were recruited for this study. 
Clinical samples were collected from each patient and cultured 
on Lowenstein-Jensen media. Detection and species 
identification were simultaneously done using Reverse Blot 
Hybridization Assay System. Also, the minimum inhibitory 
concentrations (MIC) for each isolate were determined in 7H9 
broth media for 10 antibiotics.   
RESULTS: In this study, 4 rapid and 4 slow-growing NTM 
species were isolated and identified. Mycobacterium fortuitum 
was the most common NTM species, 3/8 (37.5%), followed by 
Mycobacterium kansasii, 2/8 (25%). The cases were identified as 
pulmonary disease, 5/8 (62.5 %), disseminated infection, 2/8 
(25%), and skin abscess, 1/8 (12.5%). M. chelonae and 
Mycobacterium avium were isolated from patients diagnosed 
with disseminated infection with treatment failure. The skin 
abscess was caused by infection with M. simiae. The results of 
the MIC testing were as follows: M. kansasii and M. fortuitum 
were susceptible to amikacin (AMK); M. avium to 
clarithromycin (CLA); M. fortuitum 2/3 (67%) to ciprofloxacin 
(CIP); 1/2 (50%) of M. kansasii isolates to CLA, and M. 
chelonae to rifampin (RIF), linezolid (LIN), AMK, and CIP at 
medium and high concentrations.   
CONCLUSION: AMK showed incredible in vitro activity against 
M. kansasii and M. fortuitum. Also, M. avium was susceptible to 
CLA, whereas M. simiae and M. chelonae were resistant to the 
tested drugs in this study. 
KEYWORDS: Nontuberculous mycobacteria; Minimum 
inhibitory concentrations; Abscess; Microdilution.  
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The relative proportion of mycobacterial infections 
in HIV patients varies in different geographic 
areas, indicating the background frequency of 
latent Mycobacterium tuberculosis (MTB) 
infections in the local population (1) and the 
incidence with which NTM are encountered in the 
environment (2). Studies have identified over 150 
NTM species in the world,  most of which can 
cause mycobacterioses in humans (3,4). Recently, 
infection due to NTM has radically increased 
worldwide because of HIV infection (4). It can 
cause pulmonary infection in people living with 
HIV and may show similar clinical presentations 
such as fever, cough, weight loss, and night sweat 
steady with tuberculosis (TB) (5); both show as 
acid-fast bacilli by microscopy and discrimination 
needs biochemical or molecular tests (6). The 
global epidemiology of NTM disease is 
compromised, because the infections were not 
reported in most parts of the globe. In Asia, the 
epidemiological studies of NTM disease have not 
been population-based.  In 2005, a study conducted 
in Japan revealed that the prevalence of pulmonary 
NTM was 33 to 65 per 100 000, with the most 
dominating cases being M. avium complex (7). In a 
meta-analysis done in Iran in 2015, it was found 
that the prevalence of NTM among culture positive 
cases for TB diagnosis was 10.2%, and M. 
kansasii, M. simiae, M. gordonae, M. 
scrofulaceum, and M. chelonae were the most 
prevalent species (2).   
The drug regimen used for treating MTB is 
usually ineffective in treating NTM, because many 
of NTMs are naturally resistant to those drugs (4). 
Therefore, molecular identification is needed to 
differentiate NTMs at species level and also from 
MTB complex. Moreover, drug susceptibility 
testing is essential for selecting effective and 
appropriate chemotherapy treatment in HIV 
coinfected patients (8). 
Reverse Blot Hybridization Assay System for 
the identification of mycobacterial species (REBA 
Myco-ID) is a reliable molecular method for rapid 
identification of NTM. This method is based on 
line probe technology and has been designed such 
that it can simultaneously differentiate 21 MTB 
and NTM species using PCR, followed by reverse 
blot hybridization assay. The high sensitivity and 
specificity with outstanding reproducibility makes 
this method a highly suitable tool for rapid 
screening of clinical isolates in high prevalence 
mycobacteria-HIV coinfection settings. 
The aim of this study was to identify the 
incidence of nontuberculous mycobacteria and the 
clinical manifestations of the disease. Moreover, it   
explores the drug susceptibility profile of the NTM 
species among HIV patients in Tehran province. 
 
MATERIALS AND METHODS 
 
Study area: This study was conducted in Tehran, 
the capital city of Iran and Tehran province. It is 
located in the north of the country, with a 
population of about 8.7 million in the city and 15 
million in the larger metropolitan region of the 
Greater Tehran. Also, Tehran is the most populated 
city in Iran and in Western Asia 
(https://www.amar.org.ir/Portals/1/Iran/90.pdf). 
Study population: All HIV seropositive patients 
presenting for HIV care and treatment services at 
Emam Khomeini Referral Hospital and 5 health 
centers in Teheran province who were diagnosed 
with mycobacterial diseases between April 2018 
and July 2019 were recruited for this study. A total 
of 216 HIV patients identified to have one or more 
of the classic symptoms of mycobacterial 
infections such as fever, night sweats, cough, and 
weight loss were included in the study. The sputum 
samples were obtained from the patients on spot 
and the next morning. Other samples such as blood, 
cerebrospinal fluid (CSF), and stool were also 
obtained from the patients. 
Laboratory tests and culture: Based on the 
guidelines of the National TB Control Program, 3 
sputum samples were collected from each patient. 
According to the modified Petroff’s method, the 
sputum specimens were homogenized and 
decontaminated with 4% NaOH solution (9). The 
clinical specimens were examined for the presence 
of acid-fast bacilli (AFB) by AFB smear. The 
decontaminated specimens were cultured on solid 
Lowenstein-Jensen (LJ) and middlebrook 7H9 
broth medium. DNA was extracted from the 
culture positive specimens for molecular analysis. 
DNA was extracted using DNA extraction 
solutions (MolecuTechREBA Myco-ID kit), 
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according to the manufacturer’s manual. Briefly, 
50 mL of the DNA extraction solution was added 
to the prepared colony in a microtube and vortexed 
for 1 minute and heated at 100oC for 10 minutes 
using a thermomixer.   About 3-5 µL of the 
supernatant was used as a template for polymerase 
chain reaction (PCR). 
Species identification: In addition to biochemical 
tests (Niacin and nitrate reduction test) and 
phenotypic (pigmentation profile and rate of growth) 
testing, the Reverse Blot Hybridization Assay 
(REBA) System was used for the detection and 
identification of M. tuberculosis complex and 
nontuberculous mycobacteria species. The REBA test 
was based on reverse-hybridization of mycobacterial 
specific probe and amplified products for rpoB gene. 
The whole process of REBA was divided into 4 steps: 
(1) DNA extraction from clinical specimens, (2) 
multiple PCR amplification of target gene using 
specific primers, (3) reveres blot hybridization, and 
(4) color development by chromogenic reaction 
(colony pigment) (10). PCR was performed on the 
DNA samples using the methodology described 
below: predenaturation at 94oC one cycle for 5 
minutes, (denaturation at 94oC for 30 seconds, 
annealing at 68oC for 30 seconds) for 45 cycle, and 
final elongation at 72oC Co one cycle for 7 minutes. 
The PCR product was used for reverse blot 
hybridization. The data were interpreted according to 
the provided data sheet; the marker lane was aligned 
with the respective lines on the sheet as shown in 
Figure 1. 
Figure 1: Simultaneous identification of NTM species 
and MTB complex Myc; cross-reactive of bacteria 
except mycobacteria, HC; Hybridization control     
 
Drug susceptibility testing: The drug 
susceptibility pattern of NTM was examined using 
7H9 broth media for 10 antibiotics, including 
ethambutol (EMB), rifampin (RIF), isoniazid 
(INH), amikacin (AMK), clarithromycin (CLA), 
ciprofloxacin (CIP), imipenem (IMP), linezolid 
(LIN) cefoxitin (CET), and azitromycin (AZT). 
The minimum inhibition concentrations (MIC) 
were established by microdilutions in middlebrook 
7H9 broth base on polystyrene 96-well (12 
columns and 8 rows) plates based on the Clinical 
and Laboratory Standards Institute (CLSI) 
guidelines and published studies. A 50 µL of broth 
media was added to all wells from column 1 to 10 
on microplate.  For the stock solution of each drug, 
a final high working concentration was prepared in 
1000 µL broth medium in separate microtube. A 50 
µL of the high working concentration of each drug 
was added to the corresponding wells on first row 
from column 1 to 10, with each well containing 50 
µL broth media by using multichannel pipette, 
serial dilutions were prepared from top to bottom 
(first row to 8th row) for each column (1 to 10) by 
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transferring 50 µL (mix gently for each moves) and 
finally discarded into 11th column for antibiotic 
control (such that each row contained 10 drugs, 
whereas each column contained a single drug). The 
following final drug concentration ranges were 
used in the present study: 1 to 128 µg/mL of RIF; 1 
to 128 of INH; 0.5 to 64 µg/mL of EMB; 0.5 to 64 
µg/mL of AMK; 0.25 to 32 µg/mL of CIP; 0.5 to 
64 µg/mL of CLA; 1 to 128 µg/mL of AZT; 0.5 to 
64 of LIN; 2 to 256 of CEF, and 0.5 to 64 µg/mL of 
IMP. Opacity of the suspension was adjusted to 
match Mc Farland 1 standard with saline to obtain 
a stock suspension of approximately 1.5 × 
108 colony forming units (CFU)/ml for slow-
growing and 0.5 Mc Farland approximately 0.5 × 
107 CFU/ml rapid-growing NTM. About 100µl of 
the suspension was transferred to 4900µl (50:5000) 
of broth media, and then, 50µl of the prepared 
bacterial suspension was transferred to each well in 
columns 1 to 10 of the 96 well microplate and 
sealed in a plastic bag. Subsequently, the 
microplate was incubated at 37oC. After the third 
day of incubation at 37oC, the MIC of each drug 
was determined each day up to the last day of the 
incubation period (the last day of the third week). 
Detailed information can be found in the study 
protocol 
(https://dx.doi.org/10.17504/protocols.io.nu5dey6).  
Data analysis: Data were analyzed using SPSS 
software. Also, REBA Myco-ID data sheet, 
provided by the manufacturer, was used to interpret 
the species identification data.  
Ethics statement: The study protocol was 
approved by the ethics committee of the Vice-
Chancellor for Research Affairs in Tehran 





Patient characteristics and clinical features: In 
the present study, 216 participants, 57 (26.4%) 
females and 159 (73.6%) males, confirmed to be 
HIV seropositive and suspected of having 
mycobacterial infections were recruited. The age 
range of the patients was 14-85 years, with the 
mean age of 40.14 and standard deviation of 11.42. 
More than 93% of the samples collected were 
sputum and 2% were CSF. Among the samples, 
21/216 (9.9%) were smear positive whereas 28/216 
(13%) were culture positive for mycobacteria 
(NTM and MTB complex) (Table 1); 8/216 (3.7%) 
of the sample were positive for NTM species. The 
NTM species isolated in the present study 
included: slow-growing species, Mycobacterium 
kansasii, Mycobacterium. simiae, and 
Mycobacterium avium, and the rapid-growing 
species, Mycobacterium fortuitum, and 
Mycobacterium chelonae . Among the 8 NTM 
isolates, 4/8 (50%) were rapid-growing species, 
and the others 4/8 (50%) were slow-growing. 
According to the biochemical test in the present 
study, only M. simiea was positive for niacin test, 
whereas M. kansasii and M. fortiutum were 
positive for nitrate test. Moreover, only the colony 
of M. kansasii cultured on LJ changed color to 
yellow 48 hours after light exposure, but none of 
the other cultures showed color change. 
 
Table 1: Baseline characteristics of sample culture. 
 
 Culture Negative N (%) Culture positive N (%) 
Demographic   
Age (year) 40.33 38.73 
Female 54 (94.7%) 3 (5.3%) 
Male 134 (84.3%) 25 (15.7%) 
Specimen   
Sputum 177 (88.5%) 23 (11.5%) 
Blood 3 (75%) 1 (25%) 
CFS 5 (83.3%) 1 (6.7%) 
Pleural aspiration 3 (75%) 1 (25%) 
Stool 1 (50%) 1 (50%) 
Abscess  - 1 (100%) 
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The male to female ratio of the patients in this 
study was 7:1. Pulmonary diseases were observed 
in 5/8 (62.5 %) patients who were tested for NTM 
positive species. The disseminated infections 
caused by M. chelonae and M. avium were seen 
in 2/8 (25%) of the cases. Similar clinical 
manifestations were observed including 
productive cough, shortness of breath, 
bronchiectasis, and emphysema. Night sweating 
and chest pain were the main manifestations of 
disseminated infection. One case (1/8) was a local 
infection caused by M. simiae, isolated from a skin 
abscess of a 28-year old man who presented with 
low-grade fever (Table 2). Also, M. chelonae was 
isolated from a hemophilic 34-year old female 
patient with disseminated infection; blood, CSF, 
bone marrow, and sputum samples were smear and 
culture-positive in this patient. The patient had 
been treated for one year extensively with first and 
second-line antituberculosis medications, including 
RFM, INH, EMB, pyrazinamaid, and AMK, based 
on WHO recommendation for TB treatment. M. 
avium was also similarly isolated from a 36-year 
old man diagnosed with disseminated infection. 
Smear and culture of bone marrow aspirate, blood, 
CFS, sputum, and stool samples were positive for 
this species in the patient. This patient was 
admitted to the hospital very late at the critical 
stage of the disease. Both species isolated from the 
patients with disseminated infections were resistant 
to the recommended dosage used for treating TB 
patients. 
 
Table 2: The demographic data of patients and NTM by category 
Variables N (%) Unknown outcome N (%) Poor outcome N (%) 
NTM cases 8 6 (75) 2 (25) 
Female 1 0 1 (100) 
Male 7 (87.5) 6 (75) 1 (12.5) 
NTM location    
Pulmonary 5 (62.5) 5 (100) 0 
Extra-pulmonary 3 (37.5) 1 (33.3) 2 (66.7) 
Growth rate    
Rapid growing 4 (50%) 1 (20) 1 (20) 
Slow growing 4 (50%) 2 (66.7) 1 (33.3) 
Microbiology    
M. kansasii 2 (25) 2 (100) 0 
M. simiae 1 (12.5) 1 (100) 0 
M. avium 1 (12.5) 0 1 (100) 
M. chelonae 1 (12.5) 0 1 (100) 
M. fortuitum  3 (37.5) 3 (100) 0 
 
Species identification: Among the 28 culture-
positive isolates, 8/28 (28.5%) were identified as 
NTM isolates using biochemical test, growth rate, 
and pigmentation profile. Furthermore, the Reverse 
Blot Hybridization Assay System kit was used for 
species identification.  
Phenotypic drug susceptibility patterns of the 
NTMs isolates: The MIC values of M. kansasii, M. 
fortuitum, M. avium, M. simiae, and M. chelonae 
are presented in Table 3. The pattern of drug 
susceptibility for the NTM isolates varied between 
the species and strains. M. kansasii and M. avium 
complex were more susceptible to RIF, AMK, and 
CLA from the tested drugs. M. fortiutum was 
more susceptible to CIP, CAL, and LIN; however, 
the susceptibility of M. chelonae to RIF, AMK, 
CIP, and LIN was at a higher level of 
concentration. None of the NTM isolates was 
susceptible to INH, and IMP at any antibiotic 
concentration range. Only one isolate belonging to 
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M. kansasii was susceptible to EMB at MIC = ≥8, 
whereas the remaining isolates, 7/8 (87.5%), 
showed resistance to EMB even at the highest 
concentration. All the rapid- and slow-growing 
NTM isolates, 8/8 (100%), were resistant to INH 
and IMP at the highest concentration and both 
groups showed high susceptibility to RIF and 
AMK. 
 














Isoniazid (INH) >128 1 (100) 2 (100) 3 (100) 1(100) 1(100) 
Rifampin (RIF) 2 1 (100)     
8  1 (50)  1 (100)  
32  1 (50) 1 (33.3)   
64   1 (33.3)  1 (100) 
≥128   1 (33.3)   
Ethambutol (EMB) 8  1 (50)    
32   1 (33.3)   
>64 1(100) 1 (50) 2 (66.7) 1 (100) 1 (100) 
Amikacin (AMK) 4  1 (50)    
8   1 (33.3)   
16  1 (50)  1 (100)  
32   2 (66.7)  1 (100) 
>64 1(100)     
Ciprofloxacin (CIP) 2   1(33.3)   
4   1(33.3)   
8 1(100)     
16   1 (33.3) 1 (100) 1 (100) 
>32  2 (100)    
Clarithromycin 
(CLA) 
2  1 (50)    
4    1 (100)  
16  1 (50)    
>64 1 (100)  3 (100)  1 (100) 
Cefoxitin (CEF) 128    1 (100)  
>256 1 (100) 2 (100) 3 (100)  1 (100) 
Linezolid (LIN) 32   3 (100) 1(100) 1 (100) 
>64 1 (100) 2 (100)    
Azithromycin (AZT) 16   2 (66.7)   
32   1 (33.3)   
>128 1 (100) 2 (100)  1 (100) 1 (100) 





A number of Mycobacterium species other than 
MTB have also been identified as human 
pathogens (11,12). NTM and MTB are 2 different 
pathogens with similar epidemiological and clinical 
features, which are difficult to differentiate in 
resource limited settings. The standard medications 
used for MTB treatment are ineffective against 
NTM (12). Consequently,  it is important to 
increase the efficiency and accuracy of diagnostic 
tools for the diagnosis of NTM and MTB infections 
to initiate the appropriate medication (12,13).  The 
treatment of NTM depends on the type of species 
and individual strains. Therefore, early 
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identification is critical for the treatment of the 
disease (14). In the recent century, biochemical 
tests have been replaced by molecular methods for 
the characterization of new species, and NTM 
detection at a subspecies level, which is extensively 
helpful in facilitating treatments (15,16). It has 
been suggested that sputum samples alone may not 
be sufficient for the diagnosis of NTM infections. 
The symptoms are also variable, including chronic 
cough with or without sputum production and chest 
pain due to pulmonary infection (17).  
To the best of the knowledge of the authors, 
the present study is the first to investigate the 
incidence of NTM-HIV coinfection in Tehran, Iran. 
A total of 216 HIV patients diagnosed with 
coinfection with mycobacteria were included in 
this study. Molecular assays were used for the 
simultaneous identification of NTM species and 
MTB complex. In addition to traditional 
biochemical identification, REBA Myco-ID 
molecular diagnostic kit was used for the detection 
and identification of NTM species (Figure 1). The 
use of phenotypic characters such as pigment 
production (chromogenic) and rate of growth, 
together with biochemical tests such as niacin 
production and nitrate reduction tests may be 
adequate for the identification of some of the 
clinically relevant mycobacterial species. However, 
phenotypic characters and biochemical analysis 
might occasionally fail to reach ultimate 
identification (18). In this study, 5 species of 
NTMs were identified (M. kansasii, M. fortuitum, 
M. avium, M. chelonae, and M. simiae). Also, M. 
fortiutum (3 isolates) and M. kansasii (2 isolates) 
were the most prevalent species. This result is 
similar to that of  previous studies in Iran, even 
though  they were conducted on different 
population groups (19). In the present study, 
patients with Pulmonary diseases 5/8 (62.5%) had 
similar clinical manifestations even though the 
causative agents belonged to different species. 
Also, 2/8 (25%) patients with disseminated 
infection mainly presented with chest pain, but the 
patient who was diagnosed with local skin abscess, 
1/8 (12.5%), had no significant symptom. Many 
evidences have shown that MTB infections overlap 
with NTM infections, indicating that smear, and 
culture-positive TB cases may also be positive for 
NTM cases. Because of the considerable overlap of 
clinical signs and symptoms such as emphysema, 
bronchiectasis and lung cavitation,  and other chest 
x-ray appearance of MTB and NTM lung disease, 
it is mandatory to identify the organism in order to 
provide appropriate treatment for the patients with 
effective medications (18). If undetected, this 
overlap may be reported as drug-resistant MTB, 
even though the resistance was due to NTM 
species. Moreover, the high rate of NTM is 
probable due to treatment failure (12).  
The results of this study showed that the 
incidence of NTM to MTB complex in the HIV 
coinfected patients was 1:2.5 in Tehran province; 
8/28 (28.6%) of culture positive samples diagnosed 
with MTB). A research study conducted in Iran 
found that out of 117 isolates suspected of MDR-
TB, about 30% were misdiagnosed as MDR-TB, 
although further molecular identification revealed 
NTMs, which are resistant to anti-TB drugs. In 
addition, M. kansasii was the most prevalent 
species in their study (12, 20). 
The research study conducted on all TB-
infected patients in Nigeria reported that out of the 
16.5% of sputum isolates and culture-positive cases 
considered to be MTB, upon molecular 
identification, 4% were identified as NTM 
infections (21). On the other hand, a study 
published in 2013, which assessed the prevalence 
of NTM in Nigeria, found that out of 1603 alleged 
TB cases, 15% were identified as NTM infections 
(22).  
The epidemiological studies of NTM diseases 
have not been population-based in Asia. A study 
conducted in Japan reported a prevalence of 33 to 
65 per 100 000 for NTM, although M. avium 
complex was the most prevalent in the region. In 
contrast, a study conducted in Southeast Asia 
indicated that out of 1060 HIV-infected 
individuals, 223 (21%) were NTM positive, and 
only 19 (2%) had NTM disease of whom 9 were 
pulmonary cases (7). The results of their study are 
consistent with those of the present study in 
prevalence, but in their studies, the occurrence of 
pulmonary cases was less than the present study.  
The criteria for drug susceptibility testing for 
NTM have been established by the Clinical and 
Laboratory Standards Institute (CLSI). The CLSI 
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also recommends drug susceptibility methods and 
breakpoints for drugs used for treating NTM 
diseases (23). It has been proven that there is 
dissimilarity among individual NTM strains 
towards the susceptibility of an individual drug. 
Each strain needs its own treatment that should be 
decided on the basis of the outcome of drug 
susceptibility tests (4,23). Nevertheless, no 
molecular assay has been developed which is able 
to replace culture-based susceptibility method in 
mycobacteriology laboratory; nor is there an 
available molecular method for confirming the 
presence of resistance gene. Therefore, the CLSI 
guidelines recommends broth microdilution 
method as the gold standard method for 
determining the drug susceptibility pattern of 
NTMs (4,18). 
The results of this study are consistent with that 
reported by other research studies on MIC and 
numbers (%) of resistant strains. However, few 
other studies obtained results which are different 
from that of the present study (24). Based on the 
CLSI guidelines, the MIC for each isolate of NTM 
was determined (Table 3). In this study, it was 
found that imipenem and isoniazid were less 
effective against NTM isolates. M. simiae was 
isolated from a local skin abscess in a 28-year old 
male patient. This species was less resistant to RIF 
and CIP, but showed high resistance to other tested 
drugs. It was the only isolate with the highest MIC 
value (MIC > 64 µg/mL) against amikacin, while 
the other isolates had less MIC values. This isolate 
was also resistant to the entire drugs included in 
this study.  The M. chelonae isolate was susceptible 
to RIF, AMK, CIP, and LIN at high concentrations, 
but it was resistant to all other tested drugs even at 
high concentrations. The patient infected with this 
bacterium had been extensively treated for 1 year 
in the hospital with RIF, INH, EMB, and 
pyrazinamide for 2 months, followed by INH and 
RIF for 4 months. However, blood, sputum, and 
CFS smear remained positive. Then, the attending 
physicians switched to a second-line drug, 
amikacin, to treat the patient. Since the isolate was 
resistance at the standard dosage for the treatment 
of TB, the treatment outcome was poor, which 
resulted in the death of the patient. Another patient 
infected with M. avium with a highly disseminated 
infection involving the bone marrow, presented late 
to the hospital, and unfortunately passed away 
before the culture result was obtained. The 
susceptibility of the isolate depends on 
concentration. At medium concentration, it is 
susceptible to RIF and AMK. However, it’s 
susceptible only to CLA while the 
susceptibility to LIN was at higher 
concentration (≥32 µg/mL). The MIC for EMB, 
CEF, and AZT were higher than the concentration 
range used in this study. A previous study reported 
that the MIC values of most M. avium complex 
(MAC) isolates were beyond the doses suggested 
by pharmacokinetics for the treatment of the 
disease, particularly with EMB, RIF, and LIN (25). 
Moreover, research studies have indicated that the 
drug susceptibility pattern of MAC varies from 
region to region in the world (26). In this study, 2 
of the patients with pulmonary disease were 
infected with M. kansasii, and the isolates 
produced yellow pigments as the culture was 
exposed to light. All M. kansasii isolates were 
susceptible to AMK, and only one (50%) isolate 
was susceptible to CLA and EMB.  These isolates 
were susceptible to RIF at high concentration range 
and resistance to INH, CEF, LIN, IMP, and AZT at 
the highest concentration range (Table 3). A study 
conducted  in Taiwan found that of the total M. 
kansasii isolates, 27% were resistant to INH, 
21.6% to RFM, 73% to EMB, and 2.7% to AMK, 
but no resistance to CLA was identified (24).  A 
case study reported that INH was ineffective for the 
treatment of M. kansasii in  HIV-infected patient 
(27). Also, research studies conducted in Iran, 
Brazil, and Taiwan confirmed that M. kansasii 
isolates were susceptible to CLA  (4). On the other 
hand, a study conducted in Taiwan in 2009 
reported that all M. kansasii isolates were 
susceptible to LIN, which disagrees with the 
finding of this study (24). All M. fortiutum isolates 
were susceptible to AMK, similar to M. kansasii 
isolates, even though the 2 groups had different 
growth rates. The present study found that 2/3 
(66.6%) of M. fortiutum isolates were susceptible 
to CIP, and all the isolates (3/3) were resistant to 
the remaining tested drugs. In the recent year, a 
research study reported from China indicated that 
all M. fortiutum (17/17) isolates were extremely 
resistant to RIF, INH, and EMB (28), which is 
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consistent with the results of this study. Other 
previous studies reported that M. fortuitum isolates 
were susceptible to CIP and AMK at variable MIC 
ranges. On the other hand, except for RIF and CIP, 
M. simiae showed a high resistance rate to AMK, 
CLA, IMP, CEF, LIN, INH, and EMB.  
In this study, the treatment outcome for the 6 
patients was not obtained, because they were either 
lost to follow-up or moved to other provinces. Of 
the 8 patients referred to the TB laboratory, only 2 
underwent anti-TB first-line drug susceptibility 
test. The remaining patients underwent only smear 
and culture testing based on the requests from the 
hospital and health centers. We suspect that those 
patients treated with first-line antituberculosis 
drugs were infected with isolates that were resistant 
to the anti-TB medications, which most probably 
resulted in treatment failure. The most significant 
limitation of this study is that the prevalence of 
NTM-HIV infections was relatively low in Tehran 
province; therefore, it is difficult to generalize the 
drug susceptibility patterns for other NTM strains 
globally. It is difficult to distinguish pulmonary 
tuberculosis from NTM lung diseases. Also, 
effective drugs for treating NTM have not yet been 
developed and standardized. Therefore, differential 
diagnosis of pulmonary TB from NTM lung 
disease is critical, and should be followed by 
determining MIC for the recommended drugs to 
treat HIV-mycobacteria coinfection. Molecular 
identification, culture, and determining MIC for 
individual isolates are the gold standard for 
facilitating rapid and effective treatment in NTM-
HIV coinfected patients. In the present study, 
AMK showed incredible in vitro activity against M. 
kansasii and M. fortuitum. However, M. avium was 
resistant to the entire tested drugs, except for CLA. 
Based on the results of this study, we recommend 
updating the decisions on NTM treatment 
through periodic and long-term assessment of 
radiological changes, symptoms, and 
mycobacterial culture results. Moreover, effective 
communication among laboratories, clinicians, and 
radiologists leads to an optimized outcome in the 
disease management though population-based 
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